Tenil http://www.tenil.net/ Fri, 11 Jun 2021 21:29:56 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.2 https://www.tenil.net/wp-content/uploads/2021/05/tenil-icon-150x150.png Tenil http://www.tenil.net/ 32 32 Unvaccinated adults are more likely to be uninsured, study finds https://www.tenil.net/unvaccinated-adults-are-more-likely-to-be-uninsured-study-finds/ https://www.tenil.net/unvaccinated-adults-are-more-likely-to-be-uninsured-study-finds/#respond Fri, 11 Jun 2021 20:31:43 +0000 https://www.tenil.net/unvaccinated-adults-are-more-likely-to-be-uninsured-study-finds/

American adults who have not yet been vaccinated against Covid-19 are more likely to be uninsured and have lower incomes, according to a Kaiser Family Foundation report released on Friday.

Among people under 65, those without insurance represent 24% of the unvaccinated population, while only 12% of those insured have not received the vaccine, according to the report. About two-fifths of all unvaccinated adults (42%) report earning less than $ 40,000 per year.

The data shows that while the federal government is making efforts to improve access to the Covid-19 vaccine for uninsured people, these people may still be difficult to reach or not understand how the United States is deploying vaccines. Even though the vaccines are free for everyone, a third of those polled who say they take a “wait and see” approach to the vaccine also say they are worried about having to pay for it.

The Health Resources and Services Administration is helping people without insurance access Covid-19 treatment and vaccinations through its uninsured COVID-19 program, which reimburses providers at national Medicare rates for services.

Many states, public health departments, and employers across the country are offering incentives to make those who are reluctant more eager to be vaccinated.

Incentives might work

The report found that 46% of those who want to ‘wait and see’ how the vaccine works for others said they would be more likely to get the vaccine if it was offered in a place they normally go to for a while. to be treated. In this same group, about two-fifths said they would be more likely to get stung if it was necessary to fly on an airplane (41%) or attend large gatherings (40%).

Many adults in the “wait and see group” and those who have said they “definitely will not” get vaccinated are concerned about the safety of the vaccine, according to the report. Concerns differ from group to group and range from the impact of the vaccine on fertility to (unfounded) worries about having to pay for the vaccine and getting the vaccine in a place of trust.

The main demographic differences between these two groups focus on racial and ethnic identity, according to the report.

Half of the people in the “wait and see” group are people of color. Throughout the deployment, black and Hispanic adults said they would “wait for him to be available for a while to see how it worked for others,” the KFF revealed.

Adults who say they will “definitely not” get a Covid vaccine are “overwhelmingly” white – 70% versus 49% of the “wait and see” group, according to the report.

Black and Hispanic adults lag behind in immunization rates in part because of difficulty accessing immunization locations and services. But the current awareness is aimed at bridging the gap, the KFF said.


Source link

]]>
https://www.tenil.net/unvaccinated-adults-are-more-likely-to-be-uninsured-study-finds/feed/ 0
Galaxy Tab S7 FE release date may have been pushed back https://www.tenil.net/galaxy-tab-s7-fe-release-date-may-have-been-pushed-back/ https://www.tenil.net/galaxy-tab-s7-fe-release-date-may-have-been-pushed-back/#respond Fri, 11 Jun 2021 16:43:59 +0000 https://www.tenil.net/galaxy-tab-s7-fe-release-date-may-have-been-pushed-back/

When Samsung revealed the Galaxy Tab S7 FE at the end of last month, it only indicated that the tablet would be available in certain regions from June. Then yesterday, June 10, the company announced that sales had started in Russia.

It will be at least a month before the tablet becomes widely available if a new report from a South Korean exit (via SamMobile) is to be believed.
The publication says that the production of the Tab S7 FE has been derailed by the global chip shortage and a new wave of Covid cases in Vietnam.

Most of Samsung’s smartphone and tablet production is concentrated in Vietnam

Samsung was apparently on track to launch slate in South Korea and other markets this month, as evidenced by the fact that it obtained the necessary certification from the National Radio Research Agency (RRA) in may.

Vietnam’s latest coronavirus outbreak hit industrial production centers in the north, including factories in Bac Ninh and Thai Nguyen provinces where Samsung tablets and around half of its smartphones are apparently manufactured.

The chip shortage also continues to be a problem. Earlier it was reported that the release of Samsung’s new mid-range phones, the Galaxy A52 and A72 have been delayed in various markets due to the issue. And now it has spread to the Galaxy Tab S7 FE.

This is not surprising, given that Slate apparently has the Snapdragon 750G under the hood and we already know that Qualcomm is struggling to keep up with demand. An industry official has reportedly said the tablet will be available in July.

The Tab S7 FE is a slimmed down version of last year’s Galaxy Tab S7. the The Android tablet has a 12.4-inch screen, an 8 MP rear camera, a 5 MP front snapper and a 10,090 mAh battery. It comes with the S Pen stylus and will be available in 4GB / 64GB and 6G / 128GB variants with the option to expand storage up to 1TB.

In the UK the price starts at £ 589 (~ $ 833) and in Russia the 64GB model costs 49,990 (~ $ 692). The US price will be expected to fall somewhere in between.


Source link

]]>
https://www.tenil.net/galaxy-tab-s7-fe-release-date-may-have-been-pushed-back/feed/ 0
Think deeply about the things many ignore https://www.tenil.net/think-deeply-about-the-things-many-ignore/ https://www.tenil.net/think-deeply-about-the-things-many-ignore/#respond Fri, 11 Jun 2021 12:30:28 +0000 https://www.tenil.net/think-deeply-about-the-things-many-ignore/

If one were to come up with a list of exciting dinner topics, it’s reasonable to think veganism might take a look while climate change might get the nod for the second act. However, a topic that has an intrinsic connection to both of the above – agricultural chemicals – will rarely be at the top of the list. That’s not to say that dinner conversation is the litmus test for topics worth discussing, just that some issues may be seen as overly specialized.

But people are clearly starting to think more about how our food is processed before it hits our plates and, more importantly, how it is produced. This is where Nicola Mitchell comes in. As the founder and CEO of agrochemicals company Life Scientific, Mitchell has made a career of thinking deeply about things many ignore.

“It’s a spiritual practice,” she explains as we trace her career and the foundations of her business in a conversation on Zoom. “It’s a labor of love and that doesn’t mean that we don’t have our ego and that we really want to be successful in traditional terms… but none of it matters in relation to the cost of what we are doing. let’s do. ”

Reverse engineering

What she and her company are doing is creating generic versions of chemicals used for agricultural purposes – such as herbicides, fungicides, and insecticides – by reverse engineering those products. Put simply, Mitchell’s company aims to better recreate the recipe for a product to sell under a different name, a process that consumers of some longtime pharmaceuticals will be familiar with. The difference is that Mitchell wants to do it “better than multinational quality” and “for less”. In a market Mitchell calls an “oligopoly,” dominated by big players like Syngenta, BASF and Bayer, these goals are arguably difficult to achieve.

“These large multinationals are built for new molecules… [not] for older existing molecules. And they try to keep us out of that space and we say ‘no’ to that and ‘we don’t accept your limits’… we really want to position ourselves as the number one disruptor of this oligopoly.

Just like in pharmaceuticals, products have a shelf life of about 20 years, after which patent protection disappears. And it is in this market segment that Life Scientific is active. Unlike pharmaceuticals, governments are not as efficient at promoting and purchasing generic products which are often cheaper but with the same formulation. Mitchell took it upon herself to “remind multinationals of this, so please move on.”

This approach has not always been straightforward. In fact, it sometimes forced Mitchell to fight in court. Last year, Life Scientific won damages after winning a series of lawsuits in Germany against regulators it accused of unfairly delaying the licenses for its products.

“All that I want [regulators] to see is that we work very hard, we deliver products that deserve a place, and what better than multinational quality at a lower cost? “

Of course, reverse engineering pre-existing recipes is not the end for Mitchell. Loftier is still its goal of “reverse engineering mother nature”. Simply, the ambition here is to better understand the reasons why things happen biologically.

“I don’t want to end up in snake oils,” she explains. “I’m a scientist, so I want to understand mother nature. So that means if this plant extract works, what works.

Food

All of Mitchell’s ambitions point to a world that is changing at least when it comes to the way food is consumed. But she is clearly excited. “We’re in a golden age… because we’ve never experienced so much, we’ve never had so many choices, so many options. I eat chia seeds in my porridge for goodness sake.

Great if you like chia seeds, maybe not so good if you like beef, given Mitchell’s prediction that the way we currently produce meat is “going to be okay.” And it remains to be seen whether the fact that “we can make meat in the Petri dish” will appease the most avid carnivores.

As excited as Mitchell was about her chosen line of work, it was never clear that she would end up here. Describing herself as a “blank canvas”, she initially envisioned a career in law. After a phone call with his mother’s lawyer friend and a push from his father, Mitchell chose to study chemistry at University College Cork (UCC).

Due to the lack of work opportunities in the Republic at the time, she decided to stay at UCC to do a postgraduate degree, after which she left to work at Barclay Chemicals Limited. There, her boss was “a generous man” who supported her ambition for a master’s degree in business administration (MBA) which she completed at Fordham University in New York.

Among the classmates of this program was the former CEO of Enterprise Ireland, Julie Sinnamon.

“Then after that you have to stop all education and do something with it,” Mitchell says. And so, in 1995, she created Life Scientific.

Education

But education was then, and remains to this day, important to her and her family. Mitchell hopes to learn more about coding and genetics, for example. Much of this goes back to her grandmother “who valued education more than religion.” This resulted in “high standards” on her mother’s side of the family. “You could get 99% on a test and they would ask you what happened with the 1%. ”

This approach has clearly been successful throughout the family. Mitchell’s first cousin, for example, is Samantha Power, a former US ambassador to the United Nations and recently appointed by US President Joe Biden as administrator of the US Agency for International Development.

And his own successes are remarkable. Today, Life Scientific employs over 70 people and has a portfolio of 62 registered products. The company has business operations in Great Britain, Germany, France and Spain and has partners in Eastern Europe, China and Paraguay.

It is currently submitting files to regulators in Brazil and North America with the aim of further expanding its reach.

To some extent, it is a necessary hedge. In Latin America there are two and a half growing seasons compared to that of Western Europe. And unusual weather conditions can clearly have an impact on a business that depends on agriculture. But the expansion is also part of a five-year plan to boost Life Scientific’s revenue to 250 million euros, which will put the company’s valuation at 1 billion euros.

These numbers are not far-fetched when following the growth of the company to date. Until around 2013, it was a research and development organization under a research contract. Mitchell pivoted the company, and in seven years Life Scientific increased its revenue from $ 2 million to around $ 60 million last year. This year, Mitchell notes, sales will be stable due to bad weather in France.

The French market accounts for 50 percent of the company’s sales following an agreement Mitchell reached in 2014 with InVivo, the largest agricultural cooperative group in France. The deal saw InVivo acquire 50 percent of Life Scientific and granted the company market access.

This also prompted the company to expand into Germany and subsequently acquired a Spanish entity to increase sales there.

Mitchell expects more investment to come. Long-term pension funds are her sights, but she is “open to all options.” An initial public offering seems less likely, however, due to the quarterly reporting requirements on many exchanges. “It’s so focused on the short term,” Mitchell says of government procurement.

And there’s no doubt Mitchell is here for the long haul. She explains that she does not have “the bandwidth” to sit on boards of directors, for example, and that she would be “very badly” in retirement, not that she is still at this stage of the process. life. But working hard is something she loves. Evidenced by two trophies sitting on the back of the frame of her Zoom, awards she won as EY Entrepreneur of the Year.

Family

As the national winner, Mitchell represented Ireland in the EY World Competition on Thursday. The EY contest is particularly poignant for Mitchell as she met her partner, businessman Enda O’Coineen, at the awards show a few years ago.

“Someone said to me ‘now Nicola it’s time to go out’. And I thought, ‘jeekers no, should I do it?’ But I knew the exact place to go, to go to Citywest, all those lonely contractors and there was no need to fish, ”she jokes.

Mitchell also has three children from his marriage to Patrick Ronaldson, the founder of the Rothco advertising agency (“if you saw them, you’d think I did everything right”). “We are divorced and my greatest pride is that we are a family, it is a great friendship.”

For the most part, his weekends are quiet business spent with the family. What about recreation?

“This [job] is so devouring that I can’t even read a newspaper because I don’t have the bandwidth for it. Surely she reads the Business Post, the title owned by O’Coineen? “Of course I do,” she said with a wry smile.

As we wrap up, I ask her about her thoughts on the past year and, of course, if she thinks remote working will play a role in her business in the future.

“We are an R&D center [research and development] company and I want to be the best R&D group in the world and I do not accept that it is on Zoom.

“I’m often wrong but… certainly for me, it broadens my mind hanging out with other people and you don’t get that spontaneity on Zoom.”

It’s clear Mitchell wants a lot to change in the sphere in which she operates. It is not unreasonable to forgive her if she wants certain practices to remain the same.

CV

Name: Nicola Mitchell.

Position: Managing Director and Founder of Life Scientific.

Age: 56 years old.

Lives in: Dublin.

Family: Enda partner. Children Anna, Joe and Louis.

Leadership Style: “All I know is I bring in people who are better than me and I let them go. If my presence in the room meant that people weren’t saying something they meant, it would be me defeated. People have to come up with their point of view and get rid of it completely and the best ideas win wherever they come from.

Something you might expect: Mitchell wants more transparency for consumers buying food. She suggests that blockchain – the digital ledger technology that records vast swathes of information – could play a role.

Something that might surprise: Mitchell did ballet for 14 years.


Source link

]]>
https://www.tenil.net/think-deeply-about-the-things-many-ignore/feed/ 0
Creso Pharma secures direct access to the world’s largest cannabis market with successful dual listing in the United States https://www.tenil.net/creso-pharma-secures-direct-access-to-the-worlds-largest-cannabis-market-with-successful-dual-listing-in-the-united-states/ https://www.tenil.net/creso-pharma-secures-direct-access-to-the-worlds-largest-cannabis-market-with-successful-dual-listing-in-the-united-states/#respond Thu, 10 Jun 2021 23:55:30 +0000 https://www.tenil.net/creso-pharma-secures-direct-access-to-the-worlds-largest-cannabis-market-with-successful-dual-listing-in-the-united-states/

Listing will provide Creso Pharma with access not only to deeper capital markets, but also to the rapidly growing North American cannabis industry.

The long-awaited dual listing of Creso Pharma (ASX: CPH) shares in the US has finally taken place, with the share expected to start trading on the OTCQB market from June 11.

The listing plan has been in the works for some time and is expected to unlock significant shareholder value and provide Creso with access to the world’s largest capital market.

The move was made in the wake of growing interest from North American investors, after the company saw strong sales growth from its wholly owned subsidiary Mernova and named Bruce Linton as one of the top cannabis entrepreneurs. , as a strategic advisor.

North American investors have also sought exposure to Creso after seeing significant progress made by its US acquisition target, Halucenex.

The dual listing will provide Creso with access to deeper capital markets, allowing its institutional and retail investors in North America to invest directly in an established cannabis and psychedelic drug business.

“The company’s dual listing coincides with the growth Creso Pharma has recently achieved in the United States and North America in general,” commented Adam Blumenthal, CEO of Creso Pharma.

“Recently, we have focused on building a very strong base in the region, which is underpinned by the expansion of operations and key appointments that will provide a number of value catalysts for Australian and North American investors. Americans. “

The dual listing will also provide greater visibility for clinical studies at universities, hospitals and research centers as Creso prepares to enter the lucrative psychedelic market.

Creso Pharma will trade under code COPHF.

Legislative rear winds

The entry into the US market aligns directly with Creso’s strategic perspective to expand its operations in the region.

It will also give the company the opportunity for a potential reassessment, as it offers analysts and investors an easier comparison with its US and Canadian peers operating in the cannabis and psychedelic drug industries.

The recent strong demand for cannabis in the region follows significant cannabis legislative changes in the United States.
The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, for example, was recently reintroduced in Congress by US federal lawmakers, which would remove the federal cannabis ban.

The company is also gearing up to enter the California market, following the state’s passage of Senate Bill 519, which would legalize the use and possession of psilocybin and other psychedelic compounds.

If passed, SB 519 will approve the use of mushrooms, MDMA, LSD, mescaline and ibogaine for those eligible.

These recent developments have provided Creso and Halucenex with a major market opportunity in California and the United States.

The company intends to capitalize on these opportunities and has entered into discussions to advance partnerships and market entry strategies.

“The cannabis and psychedelic medicine sectors continue to gain traction,” the company said.
“Recent regulatory changes have left Creso in a favorable position, and it is well positioned to become a world leader in both sectors,” added Blumenthal.

Creso is also currently taking steps to gain approval from the Depository Trust Company (DTC), which would allow real-time electronic clearing and settlement in the United States for its common stock.

This decision will allow access to trading with major online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade, all of which offer trading services in the OTCQB market.

This article was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publication.

This article is not advice on financial products. You should consider getting independent advice before making any financial decisions.

You might be interested in


Source link

]]>
https://www.tenil.net/creso-pharma-secures-direct-access-to-the-worlds-largest-cannabis-market-with-successful-dual-listing-in-the-united-states/feed/ 0
Young Australians and COVID-19: More depression and anxiety, but less alcohol-related harm https://www.tenil.net/young-australians-and-covid-19-more-depression-and-anxiety-but-less-alcohol-related-harm/ https://www.tenil.net/young-australians-and-covid-19-more-depression-and-anxiety-but-less-alcohol-related-harm/#respond Thu, 10 Jun 2021 22:00:00 +0000 https://www.tenil.net/young-australians-and-covid-19-more-depression-and-anxiety-but-less-alcohol-related-harm/

Young Australians experienced increased depression and anxiety during COVID-19 restrictions in 2020 but consumed less alcohol, according to a new report from the National Drug and Alcohol Research Center (NDARC) at UNSW Sydney .

Worryingly, the increase in their mental health problems has not been offset by a greater demand for help from mental health professionals.

The researchers used survey data from 1,927 young people – with a median age of 22 – as part of the Australian Parental Supply of Alcohol Longitudinal Study (APSALS) cohort. They found that half of the cohort considered their mental health to have deteriorated in May-June 2020, compared to August 2019-March 2020.

“Young people may be disproportionately affected by certain stressors associated with the pandemic, such as the reduction of occasional working hours and the disruption of other structured activities such as higher education,” explains Emily Upton, research fellow at NDARC and clinical psychologist.

The report found that despite the rise in generalized anxiety and depression, there had been no increase in the number of young people seeking mental health support from medical professionals.

“Young people tend to have little involvement in mental health treatment and rely more on self-reliance strategies to deal with mental health issues,” Upton explains.

Delay in young people’s access to support

The report found that although the Australian government has introduced initiatives to increase access to mental health support during the pandemic, there may be a delay in young Australians accessing this support.

“Cost is a major barrier to accessing treatment for young people. The reduction in income during the pandemic may be a factor in the low rate of seeking help and, although government discounts are available, these do not cover the full cost of psychological treatment, ”Ms. Upton said.

In another report using the same APSALS survey data, researchers found that alcohol use among young people during the COVID-19 pandemic had declined.

Dr Philip Clare, biostatistician at The Prevention Research Collaboration, University of Sydney, said overall alcohol consumption among young people during the May and June 2020 restrictions has declined. “It is down 17% from February 2020, and there has been a 34% drop in the rate of alcohol-related harm.”

The report found that the changes in consumption appear to be driven by the COVID-19 restrictions.

Increase in consumption “virtually”

“Young people generally consume more alcohol outside the home, so we would expect alcohol consumption to decrease during COVID-19 restrictions. However, we have seen an increase in alcohol consumption alone and consumption “virtually” with others, ”says Dr. Clare.

Likewise, the decrease in alcohol-related harms may be due to the fact that alcohol consumption was more likely to occur alone or “virtually” with others due to the need to isolate oneself, this which reduces the risk of harm such as arguments with strangers, traffic accidents. “

The report stresses that it is also important to understand alcohol-related trends among young people so that relevant harm reduction strategies can be implemented.

“Although alcohol consumption and harms have decreased, we may see an increase in the future due to loss of tolerance,” said Dr Clare.

Read Ms Emily Upton’s APSALS report.

Read Dr Philip Clare’s APSALS report.

People can access free, confidential advice on alcohol and other drugs by calling the National Alcohol and Other Drugs Hotline – 1800 250 015.


Source link

]]>
https://www.tenil.net/young-australians-and-covid-19-more-depression-and-anxiety-but-less-alcohol-related-harm/feed/ 0
Toyota LandCruiser 300 Series 2022: official off-road specifications, interior technical details emerge https://www.tenil.net/toyota-landcruiser-300-series-2022-official-off-road-specifications-interior-technical-details-emerge/ https://www.tenil.net/toyota-landcruiser-300-series-2022-official-off-road-specifications-interior-technical-details-emerge/#respond Thu, 10 Jun 2021 19:57:15 +0000 https://www.tenil.net/toyota-landcruiser-300-series-2022-official-off-road-specifications-interior-technical-details-emerge/

A host of off-road details and interior technology highlights emerge from one of the LandCruiser’s biggest markets: Russia.

Official details of the 2022 Toyota LandCruiser 300 Series Off-Road Specifications and Interior Technology Details emerged, about 24 hours after its global unveiling on Thursday.

The new information comes from a 35-minute video released by the Russian branch of Toyota, which details approach and departure angles, ground clearance and the range of technologies inside the cabin of the new LandCruiser 300. Series.

Click on any of the images in this story to view the full gallery.


2022 Toyota LandCruiser 300 Series Off-Road Specs

The video confirms the most off-road oriented variants of the new LandCruiser 300 series with 18-inch wheels and shorter bumpers – probably the GR Sport (top right), or the entry-level model with a single front bumper (top left) – claims a 32 degree approach angle, and one 26.5 degree departure angle.

For comparison, LandCruiser 200 Series models delivered to Australia claim identical approach angles of 32 degrees, but departure angles of 24 degrees.

A ground clearance figure of 230 mm is claimed in the video – identical to the 200 series models in the Australian market – although confusingly, this applies to high-end versions with taller bumpers (with less clearance below) and 20-inch wheels, suggesting that the GR Sport and / or the entry-level model with different bumpers might be able to clear higher obstacles.

A break angle for the 300 series has not yet been confirmed, nor the vehicle’s maximum wading depth. The outgoing 200 series offers a crossing angle of 21 degrees and a maximum wading depth of 700mm.

Base model photos displayed online show 300 Series vehicles with The 18-inch wheels are wrapped in 265/65 R18 tires – 20 mm narrower than before, resulting in 31.6 inches in diameter, and 10.4 inches in width.

Meanwhile, the flagship qualities’ The 20-inch wheels are shod with 265/55 R20 rubber – conversion to 31.5 inch diameter and 10.4 inch width – made by Dunlop, as shown in the video.

As detailed in our full reveal story, the new Toyota LandCruiser 300 Series debuts an electronic version of Toyota’s Kinetic Dynamic Suspension System (known as e-KDSS), allowing the front and rear anti-roll bars to be fitted. be “disabled” for increased suspension articulation.

Permanent four-wheel drive with high and low end modes is standard, with flagship models available with three locking differentials front, center and rear – claimed to be unique to the segment.

Until five Multi-Terrain Select off-road driving modes would be offered (when the low range is engaged), adapting to different driving environments: Auto, Dirt, Sand, Mud and Deep Snow.

They join another six normal driving modes – Eco, Normal, Comfort, Sports, Sports + and Custom – which vary transmission programming, suspension behavior, engine response and, depending on the walk-around, the behavior of the air conditioning system (probably turning it off in Eco mode to save fuel).

A offroad ramp control system – which can vary between low, medium and high settings – allows the 300 Series to traverse rough terrain both uphill and downhill at a fixed speed without the driver touching the pedals.

Other off-road features on offer include a new multi-terrain monitor that makes the vehicle ‘invisible’ to show objects normally out of the driver’s view – allowing easier placement of the off-road front wheels – as well as cameras. 360 degree cameras and individual tire pressure monitors.


2022 Toyota LandCruiser 300 Series Interior Technology and Features

In addition to disclosing a number of off-road specifications and features of the new Toyota LandCruiser 2022, the Russian overview video provides an in-depth look at the interior of the four-wheel drive.

Up front, the flagship ranks instrument panel is dominated by a 12.3 inch tablet-style infotainment touchscreen with Apple CarPlay, Android Auto, and satellite navigation – a substantial upgrade from the 9.0-inch unit in the 200 series, which offered satellite navigation but lacked smartphone mirroring technology.

Drivers are greeted with a 7.0-inch digital display between two analog dials, as well as a full-color head-up display, both seated behind a leather-wrapped steering wheel with tilt and telescoping adjustment.

There is also a fingerprint reader integrated into the power button, intended to reduce theft by storing up to 10 different fingerprints, each of which can be linked to the driver’s climate preferences, seating position and station. favorite radio station.

Below the display is a metal switch panel for the air conditioning system – which offers four zones, corresponding to the outgoing “Cruiser” – and off-road controls, including a large mode selection dial that can be switched between the six on-road driving modes and the five Multi-Terrain Select off-road profiles.

Second-row passengers benefit from two of the four climate control zones on offer, as well as two 11.6-inch entertainment screens mounted on the front seat backs.

Other features available inside and out include a premium 14-speaker JBL audio system, six USB ports (two front, four rear), wireless smartphone charging , a cabin air ionizer, electric front seats, an electrically operated one-piece tailgate, and a household power outlet in the trunk.

There’s also a set of adaptive LED headlights that can change sections of their beam to avoid blinding oncoming drivers.

As noted, a range of active safety systems are offered with the 300 Series, including Autonomous Emergency Braking with Pedestrian and Cyclist Detection and Intersection Support, Adaptive Cruise Control, Blind Spot Monitoring, Alert rear cross-traffic, traffic sign recognition, and low-speed rear autonomous emergency braking for parking lots.


the 2022 Toyota LandCruiser 300 Series will go on sale in Australia in the fourth quarter of 2021 (October to December inclusive).

Models at launch will be powered by a all-new 3.3-liter twin-turbo diesel V6, Sending in progress 227kW and 700Nm via a 10-speed automatic transmission – replacing the outgoing 4.5-liter 200 kW / 650 Nm twin-turbo diesel V8. A twin-turbo petrol V6 will be offered in international markets, while a hybrid model is expected to arrive by 2025.

For everything you need to know about the new Toyota LandCruiser 300 Series, click on the links below.


Watch the full video below (although we suggest you brush up on your Russian first …)



Source link

]]>
https://www.tenil.net/toyota-landcruiser-300-series-2022-official-off-road-specifications-interior-technical-details-emerge/feed/ 0
Inogen Hires BD Vice President of Diabetes for Marketing Director to Help Expand Home Oxygen Machine Line https://www.tenil.net/inogen-hires-bd-vice-president-of-diabetes-for-marketing-director-to-help-expand-home-oxygen-machine-line/ https://www.tenil.net/inogen-hires-bd-vice-president-of-diabetes-for-marketing-director-to-help-expand-home-oxygen-machine-line/#respond Thu, 10 Jun 2021 14:05:01 +0000 https://www.tenil.net/inogen-hires-bd-vice-president-of-diabetes-for-marketing-director-to-help-expand-home-oxygen-machine-line/

With a new CEO in place and revenues rebounding from a tumultuous 2020, Inogen is looking to make its home and portable oxygen concentrator product line bigger and better than ever.

The next step? Hiring a Chief Medical Officer with decades of experience with medical technology and life science heavyweights like BD, Novo Nordisk and Sanofi.

That’s what Inogen found at Stanislav Glezer, MD, who will join the company as Marketing Director on June 21. He will lead the medical affairs, clinical research and regulatory branches of the device maker throughout its efforts to both expand its product line and broaden its current presence. in the oxygen equipment market.

Inogen currently offers five separate systems: three portable concentrators and one for home use as well as the Tidal Assist ventilator, which connects to oxygen tanks and concentrators to increase oxygen flow.

RELATED: Newly Public Inogen Gets FDA Clearance for Home Oxygen Device

In his new role, Glezer will focus largely on improving these systems and leading the development of new ones by initiating and overseeing clinical studies, he said in a statement. declaration.

“I look forward to contributing to the next phase of Inogen’s planned growth as we continue to seek ways to design patient-centered outcome studies to improve access to our best product offerings,” to enable prescribers to better serve their patients and improve our market position and value for our shareholders, ”he added.

Glezer comes to Inogen directly from BD, where he was vice president of global medical affairs in the medical device giant’s diabetes care business since 2018. Earlier this year, he also became global vice president of development. sales representative of the diabetes segment. Activities.

Prior to joining BD in 2017, Glezer served for a year as Chief Medical Officer of Adocia, a biotechnology company developing drugs to treat diabetes and other metabolic diseases.

Prior to that, he accumulated approximately two decades of experience in the pharmaceutical field. It started in the mid-1990s, when he spent two years as a product manager at Teva Pharmaceuticals in Russia, around the time he graduated in medicine from the State Medical University. and Moscow dentistry.

He then joined Pharmascience, Technilab Pharma and Berlex Laboratories – now Bayer HealthCare Pharmaceuticals – before moving to Sanofi for nearly 15 years. There he served as Vice President of Medical Affairs and Clinical Evidence and, in his last role at Big Pharma, as Global Head of Long-Acting Insulin Development and Regulatory Process Toujeo. by Sanofi.

Shortly thereafter, Glezer served as vice president of medical affairs at Novo Nordisk for a year between 2016 and 2017.

RELATED: Sanofi’s Vice President of Digital Health Jumps Ship for Pain Management Developer Remedee Labs

Inogen CEO Nabil Shabshab, who caught on the lead role in February – predicts that Glezer’s 25 years in medical, biotech and pharmaceutical technology “will be a tremendous catalyst to build a stronger Inogen and elevate our clinical capabilities overall.”

Shabshab continued, “I believe that expanding our clinical expertise and evidence base in respiratory therapy will be of great benefit to us in our efforts to drive our market development efforts to potentially increase the penetration of portable oxygen concentrators. in support of our growth strategy as well as our innovation program.


Source link

]]>
https://www.tenil.net/inogen-hires-bd-vice-president-of-diabetes-for-marketing-director-to-help-expand-home-oxygen-machine-line/feed/ 0
Tenax Therapeutics to join the Russell Microcap® Index https://www.tenil.net/tenax-therapeutics-to-join-the-russell-microcap-index/ https://www.tenil.net/tenax-therapeutics-to-join-the-russell-microcap-index/#respond Thu, 10 Jun 2021 12:30:00 +0000 https://www.tenil.net/tenax-therapeutics-to-join-the-russell-microcap-index/

MORRISVILLE, NC – (COMMERCIAL THREAD) – Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that treat cardiovascular and pulmonary disease with high unmet medical need, is expected to join the Russell Microcap® Index at the conclusion of the Russell 2021 Indexes’ annual replenishment effect after the U.S. market opens on June 28, according to a preliminary list of additions released on June 4.

Russell Microcap Membership® The index, which remains in place for one year, signifies automatic inclusion in the appropriate growth and value style indices. FTSE Russell determines membership in its Russell Indices primarily through objective market capitalization rankings and style attributes.

“Our inclusion in the Russell Microcap Index comes at an exciting time for our company, as we plan to advance our two flagship drug development programs (imatinib and levosimendan) into Phase 3 clinical trials,” said Anthony DiTonno, CEO of Tenax Therapeutics. “Over the next few months, we also anticipate a series of important research publications that will support Tenax’s pioneering approach to the treatment of pulmonary hypertension and heart failure with preserved ejection fraction. We therefore appreciate our inclusion in this widely followed index, which should increase our visibility with institutional investors at such an important time in our company’s growth.

Russell Indices are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $ 10.6 trillion in assets is compared to Russell’s U.S. indices. The Russell Indices are part of FTSE Russell, one of the world’s leading index providers. For more information on the Russell Microcap® Index and the Russell Reconstitution, see the “Russell Reconstruction” section on the FTSE Russell website.

About FTSE Russell

FTSE Russell is a global index leader providing innovative benchmarking, analytics and data solutions to investors around the world. FTSE Russell calculates thousands of indices that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the global investment market.

The expertise and products of the FTSE Russell Index are widely used by institutional and retail investors around the world. About $ 17.9 trillion is currently compared to the FTSE Russell indices. For more than 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen the FTSE Russell Indices to benchmark their investment performance and create ETFs, structured products and index derivatives.

A set of basic universal principles guide the design and management of the FTSE Russell Index: a transparent rules-based methodology is informed by committees independent of major market players. FTSE Russell is focused on applying the highest industry standards in index design and governance and adheres to the principles of IOSCO. FTSE Russell is also focused on index innovation and client partnerships with the aim of improving the breadth, depth and reach of its offering.

FTSE Russell is 100% owned by the London Stock Exchange Group. For more information visit www.ftserussell.com

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products that treat cardiovascular and pulmonary disease with high unmet medical need. The Company has a world-class scientific advisory team comprising recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan and recently published the detailed results of the phase 2 HELP study of levosimendan in pulmonary hypertension associated with heart failure and preserved ejection fraction. (PH-HFpEF) at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting. Tenax is also developing a delayed-release oral formulation of imatinib, designed to prevent gastric irritation, in a single pivotal trial according to route 505 (b) (2). For more information, visit www.tenaxthera.com.

About Lévosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It was originally developed for intravenous use in hospitalized patients with acute decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and is not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

About imatinib

Imatinib is an antiproliferative agent developed to target BCR-ABL tyrosine kinase in patients with chronic myelogenous leukemia. The inhibitory effects of imatinib on the PDGF and c-KIT receptors suggest that it may be effective in PAH. Imatinib reversed experimentally induced pulmonary hypertension and has pulmonary vasodilator effects in animal models and pro-apoptotic effects on pulmonary artery smooth muscle cells of patients with idiopathic PAH. In a phase 3 clinical trial, imatinib produced significant improvements in exercise capacity, but a high dropout rate attributed largely to gastric intolerance precluded regulatory approval.

Caution Regarding Forward-Looking Statements

This press release contains certain forward-looking statements of the Company which involve risks and uncertainties and reflect the judgment of the Company as of the date of this press release. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, matters beyond the control of the Company which could cause delays in the clinical study, the launch of new products and customer acceptance of these new products; matters beyond the control of the Company that could affect the Company’s continued compliance with Nasdaq listing requirements; the impact of management changes on the Company’s business and unanticipated unanticipated charges, costs and expenses that may arise as a result of management changes; and other risks and uncertainties as described in documents filed by the Company with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 31, 2021 and its quarterly report on Form 10 -Q filed on May 17, 2021, along with its other documents filed with the SEC. The Company disclaims any intention or obligation to update these forward-looking statements beyond the date of this press release. Statements in this press release regarding management’s future expectations, beliefs, objectives, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.


Source link

]]>
https://www.tenil.net/tenax-therapeutics-to-join-the-russell-microcap-index/feed/ 0
Drug commonly used as an antidepressant helps fight cancer in mice https://www.tenil.net/drug-commonly-used-as-an-antidepressant-helps-fight-cancer-in-mice/ https://www.tenil.net/drug-commonly-used-as-an-antidepressant-helps-fight-cancer-in-mice/#respond Thu, 10 Jun 2021 09:02:23 +0000 https://www.tenil.net/drug-commonly-used-as-an-antidepressant-helps-fight-cancer-in-mice/

PICTURE: Shirley Xi Wang, Lili Yang, and Ryan Yu-Chen Wang found that mice became more able to fight melanoma and colon tumors when treated with MAOIs. view After

Credit: UCLA Large Stem Cell Research Center

A class of drugs called monoamine oxidase inhibitors are commonly prescribed to treat depression; the drugs work by increasing the levels of serotonin, the brain’s “happiness hormone”.

A new study by researchers at UCLA suggests that these drugs, commonly known as MAOIs, may have another health benefit: helping the immune system attack cancer. Their results are reported in two articles, which are published in the journals Scientific immunology and Nature Communication.

“MAOIs have never been linked to the immune system’s response to cancer before,” said Lili Yang, lead author of the study and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA . “What’s particularly exciting is that this is a very well-researched and safe class of drugs, so reusing it for cancer isn’t as difficult as developing a completely new drug on it. would be.”

Recent advances in understanding how the human immune system naturally searches for and destroys cancer cells, as well as how tumors try to evade this response, have led to new cancer immunotherapies – drugs that stimulate the activity of the immune system in an attempt to fight cancer.

In an effort to develop new immunotherapies against cancer, Yang and his colleagues compared immune cells from melanoma tumors in mice to immune cells from animals without cancer. The immune cells that had infiltrated the tumors had a much higher activity of a gene called monoamine oxidase A, or MAOA. The corresponding MAOA protein, called MAO-A, controls serotonin levels and is targeted by MAOI drugs.

“For a long time, people have theorized about the crosstalk between the nervous system and the immune system and the similarities between the two,” said Yang, who is also an associate professor of microbiology, immunology and molecular genetics at UCLA. and member of the UCLA Jonsson Comprehensive Cancer Center. “So it was exciting to find out that MAOA was so active in these tumor-infiltrating immune cells.”

Next, the researchers studied mice that did not produce MAO-A protein in immune cells. Scientists found that these mice better controlled the growth of melanoma and colon tumors. They also found that normal mice became more able to fight off these cancers when treated with MAOIs.

Investigating the effects of MAO-A on the immune system, researchers found that T cells – immune cells that target cancer cells for destruction – produce MAO-A when they recognize tumors, which shrinks their ability to fight cancer.

This discovery places MAO-A among a growing list of molecules known as immune checkpoints, which are molecules produced as part of a normal immune response to prevent T cells from overreacting or overreacting. attack healthy tissue in the body. Cancer is known to harness the activity of other previously identified immune checkpoints to evade attacks by the immune system.

In the Scientific immunology article, scientists report that MAOIs help block MAO-A function, which helps T cells overcome immune checkpoint and fight cancer more effectively.

But drugs also have a second role in the immune system, Yang found. Unwanted immune cells known as tumor associated macrophages often help tumors evade the immune system by preventing anti-tumor cells, including T cells, from mounting an effective attack. High levels of these tumor-associated immunosuppressive macrophages within a tumor have been associated with poorer prognoses for people with certain types of cancer.

But the researchers found that MAOIs block immunosuppressive macrophages associated with tumors, effectively destroying a tumor line of defense against the human immune system. This finding is reported in the Nature Communication paper.

“It turns out that MAOIs appear to both directly help T cells do their job and prevent tumor-associated macrophages from slowing down T cells,” Yang said.

Combine MAOIs with existing immunotherapies

Yang said she suspected MAOIs might work well in concert with a type of cancer immunotherapies called immune checkpoint blocking therapies, most of which work by targeting immune checkpoint molecules on the surface. immune cells. This is because MAOIs work on MAO-A proteins, which are inside cells and work differently from other known immune checkpoint molecules.

Studies in mice have shown that one of the three existing MAOIs – phenelzine, clorgyline or mocolobemide – alone or in combination with a form of immune checkpoint blocking therapy known as PD-1 blockers, could stop or slow the growth of colon cancer. and melanoma.

Although they did not test the drugs in humans, the researchers analyzed clinical data from people with melanoma, colon, lung, cervical and pancreatic cancer; they found that people with higher levels of MAOA gene expression in their tumors had, on average, shorter survival times. This suggests that targeting MAOA with MAOIs could potentially help treat a wide range of cancers.

Yang and coworkers are already planning additional studies to test the effectiveness of MAOIs in stimulating the response of human immune cells to various cancers.

Yang said MAOIs could potentially act on both the brain and immune cells of cancer patients, which are up to four times more likely than the general population to experience depression.

“We suspect that reuse of MAOIs for cancer immunotherapy may provide patients with both antidepressant and anti-tumor benefits,” she said.

The experimental combination therapy in the study has been used in preclinical testing only and has not been studied in humans or approved by the Food and Drug Administration as safe and effective for use in humans. The newly identified therapeutic strategy is covered by a patent application filed by the UCLA Technology Development Group on behalf of the Regents of the University of California, with Yang, Xi Wang and Yu-Chen Wang as co-inventors.

###

The research was supported by Stop Cancer, the Broad Stem Cell Research Center Rose Hills Foundation Innovator Grant and Stem Cell Training Program, the UCLA Jonsson Comprehensive Cancer Center and the Broad Stem Cell Research Center Ablon Scholars Program, the Magnolia Council of Tower Cancer Research Foundation and the National Institutes of Health, including a Ruth L. Kirschstein National Research Service Award.

Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.


Source link

]]>
https://www.tenil.net/drug-commonly-used-as-an-antidepressant-helps-fight-cancer-in-mice/feed/ 0
Laptop shipment to India more than doubled to 2.5 million in Q1 2021 https://www.tenil.net/laptop-shipment-to-india-more-than-doubled-to-2-5-million-in-q1-2021/ https://www.tenil.net/laptop-shipment-to-india-more-than-doubled-to-2-5-million-in-q1-2021/#respond Thu, 10 Jun 2021 02:35:14 +0000 https://www.tenil.net/laptop-shipment-to-india-more-than-doubled-to-2-5-million-in-q1-2021/